Introduction
Company
Leadership
Supervisory board
Scientific advisory board
Investors
miRNAs and cancer
Technology & IP
Lentiviral-based miRNA overexpression library
Identification mode of action & biomarkers
Enabling next-generation drug delivery technology
Unique IP position
Scientific publications
Products
Careers
Contact
Introduction
Company
Leadership
Supervisory board
Scientific advisory board
Investors
miRNAs and cancer
Technology & IP
Lentiviral-based miRNA overexpression library
Identification mode of action & biomarkers
Enabling next-generation drug delivery technology
Unique IP position
Scientific publications
Products
Careers
Contact
Breakthrough miRNA
therapeutics tackling cancer
InteRNA Technologies Extends Series B Financing Round Totaling EUR 18.5M
9 February, 2021
read more
this website uses cookies
INFO
OK